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ABSTRACT 
Silymarin, 'one of the component of the Milk thistle seeds Silybum marianum (L.) is used in traditional food and medicine in India. In the present 
study, we investigated the antioxidant activities of Silymarin against copper-ascorbate induced toxic injury to mitochondria obtained from goat 
heart, in vitro. Incubation of isolated cardiac mitochondria with copper-ascorbate resulted in elevated levels of lipid peroxidation and protein 
carbonylation of the mitochondrial membrane, a reduced level of mitochondrial GSH and altered status of antioxidant enzymes as well as decreased 
activities of pyruvate dehydrogenase and the Kreb’s cycle enzymes, altered mitochondrial morphology, mitochondrial swelling and di-tyrosine level. 
All these changes were found to be ameliorated when the cardiac mitochondria were co-incubated with copper-ascorbate and Silymarin, in vitro. 
Silymarin, in our in vitro experiments, was found to scavenge hydrogen peroxide, superoxide anion free radicals, hydroxyl radicals and DPPH 
radical, in a chemically defined system, indicating that this compound may provide protection to cardiac mitochondria against copper-ascorbate 
induced toxic injury through its antioxidant activities. The results of this study suggest that Silymarin may be considered as a future therapeutic 
antioxidant and may be used singly or as a co-therapeutic in the treatment of diseases associated with mitochondrial oxidative stress. 
Keywords: Silymarin, Antioxidant, Copper-Ascorbate, Goat Heart Mitochondria, Oxidative Stress. 
 
INTRODUCTION 
Silymarin consists of a major active constituent, Silybinin, also 
known as silybin, obtained from a standardized extract of the Milk 
thistle seeds Silybum marianum (L.) Gaertn., family Asteraceae. It 
consists of a mixture of flavonolignans consisting of among others of 
silibinin, isosilibinin, silicristin, and silidianin. Silibinin itself is 
mixture of two diastereomers, silybin A and silybin B, in 
approximately equimolar ratio [1].  
Silymarin has clinical applications as a potential anti-hepatotoxic 
drug and it is currently used for supportive treatment of liver 
aliments [2, 3]. Silymarin is widely used for protection against 
various hepatobiliary problems in Europe [4]. It is also reported to 
offer protection against chemical hepatotoxins such as CCl4 [5], 
acetaminophen [6], phalloidin, galactosamine and thioacetamide [7] 
and alcoholic liver diseases [8]. Due to its proven hepatoprotective 
and antioxidant properties, silymarin is being used as a standard 
agent for comparison in the evaluation of hepatoprotective effects of 
plant principles [9]. In addition to its antioxidant properties, it has 
been reported to have high anti-tumor promoting activity [10] and 
has been linked to the prevention of skin carcinogenesis [10]. Recent 
studies have also reported that silymarin is an effective antiviral 
treatment for hepatitis C virus (HCV) [11]. In addition, a variety of 
studies demonstrated that silymarin exhibits anti-carcinogenic, anti-
inflammatory, anti-atherosclerotic activities [12, 13] and also 
immune-modulatory activity [10]. Protective effects of silymarin 
against gastric ulcers induced by cold-resistant stress and ischemia–
reperfusion were also reported previously [14].  
But till date there is no report available, to the best of our knowledge 
and belief, about the protective effect of silymarin against 
mitochondrial oxidative stress. Herein, we provide evidences 
perhaps for the first time, the protecting ability of silymarin against 
copper-ascorbate induced toxic injury to goat heart mitochondria, in 
vitro, and antioxidant mechanism(s) may be responsible for such 
protections.  
MATERIALS AND METHODS 
Chemicals 
Copper-chloride and ascorbic acid were purchased from Sisco 
Research Laboratories (SRL), Mumbai, India. All other chemicals 
used including the solvents, were of analytical grade obtained from Sisco 
Research Laboratories (SRL), Mumbai, India, Qualigens 
(India/Germany), SD fine chemicals (India), Merck Limited, Delhi, India.  
Silymarin  
Silymarin was gifted to us by Micro Labs Ltd. Silymarin / silybin 
sample of specifications Ref. No & Item code 100R0200S008 and 
batch no. 71315300612, manufactured by Tewa Czech Industrial 
Ltd, and analyzed by Micro Labs Ltd., Hosur, Tamilnadu as a 
brownish yellow fine powder. It was soluble in hot methanol, 
slightly soluble in ethyl acetate but insoluble in chloroform and 
water. Its 1% solution shows the pH in the rage of 4.5 to 6.0. HPLC 
analysis of the sample was carried out by Micro Labs Ltd.  
Determination of antioxidant properties of silymarin 
Hydroxyl radical (•OH) scavenging activity 
Hydroxyl radical was generated in sodium phosphate buffer (0.05 
mM, pH 7.4) with 1 mM ascorbate and 0.2 mM Cu2+ for 60 minutes in 
the presence and absence of DMSO (500 mM) and different 
concentrations of silymarin in a volume of 1 ml to determine the 
hydroxyl radical scavenging activity of silymarin in an in vitro 
system. The reaction was terminated in each case by the addition of 
0.1 mM EDTA. Methanesulfinic acid (MSA) formed during incubation 
was measured by the method of Babbs and Steiner[15] as modified 
by Bandyopadhyay et al. [16].  
Superoxide anion free radical (O2.-) scavenging activity  
Superoxide anion free radical (O2.-) scavenging activity was studied 
by following the rate of epinephrine oxidation in alkaline pH at 480 
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nm[17]. The reaction mixture had in a volume of 1 ml, 50 mM Tris-
HCl buffer (pH 10), 0.6 mM epinephrine and different concentrations 
of silymarin. The increase in absorbance due to the formation of the 
adrenochrome was followed for 7 minutes spectrophotometrically 
and the activity was calculated from the linear part in absence and 
presence of silymarin.  
Hydrogen peroxide (H2O2) scavenging activity  
Hydrogen peroxide (H2O2) scavenging activity was assayed by studying 
the breakdown of H2O2 at 240 nm spectrophotometrically [18]. 
DPPH free radical scavenging activity  
The DPPH free radical scavenging activity of each sample was 
determined according to the method described by Dutta et al. [19]. A 
solution of 0.1 mM DPPH in methanol was prepared. The initial 
absorbance of the DPPH in methanol was measured 
spectrophotometrically at 515 nm. 40 μL of silymarin solution was 
added to 3 mL of methanolic DPPH solution. The change in 
absorbance at 515 nm was measured after 30 min. The antiradical 
activity (AA) was determined using the following formula: AA% = 
100 − [(Abs: sample − Abs: empty sample)] × 100)/Abs: control  
Preparation of goat heart mitochondria (Caprine heart 
mitochondria)  
Goat heart mitochondria were isolated according to the procedure of 
Dutta et al. [20] with some modifications. Goat heart was purchased 
from local Kolkata Municipal Corporation approved meat shop. After 
collection it was brought into laboratory in sterile plastic container 
kept in ice. Then, the heart tissue was cleaned and cut into pieces. 
 Five gm of tissue was placed in 10 ml of sucrose buffer [0.25(M) 
sucrose, 0.001(M) EDTA, 0.05(M) Tris-H2SO4 (pH 7.8)] at 250C. Then, 
the tissue was blended for 1 minute at low speed by using a Potter 
Elvenjem glass homogenizer (Belco Glass Inc., Vineland, NJ, USA), 
after which it was centrifuged at 1500rpm for 10 minutes. The 
supernatant was poured through several layers of cheesecloth and 
kept in ice. Thereafter, it was centrifuged at 4000rpm for 5 minutes. 
The supernatant, thus obtained, was further centrifuged at 
14000rpm for 20 minutes. The final supernatant obtained was 
discarded and the pellet was resuspended in sucrose buffer and was 
stored at -20⁰C for further use.  
Incubation of mitochondria with copper- ascorbate 
The incubation mixture containing mitochondrial membrane protein 
(1.6 mg/ml), 50 mM potassium phosphate buffer (pH 7.4), and 0.2 
mM Cu2+ and 1 mM ascorbic acid in a final volume of 1.0 ml was 
incubated at 37 ° C in an incubator for 1 hour. The reaction was 
terminated by the addition of 40 µl of 35 mM EDTA [21].  
Protection of Cu2+-ascorbate -induced toxic injury to 
mitochondria by silymarin 
The goat heart mitochondria were co-incubated with copper-
ascorbate and four different concentrations of silymarin. After 
incubation, the intactness of mitochondria, the biomarkers of 
oxidative stress like lipid peroxidation level, reduced glutathione 
and protein carbonyl content, activities of antioxidant enzymes, 
Kreb’s cycle enzymes, mitochondrial swelling and di-tyrosine level 
were determined.  
Determination of mitochondrial intactness by using Janus green 
B stain 
After incubation, the mitochondrial sample was diluted 1:200 by 
using 50 mM phosphate buffer (pH 7.4). Then, the mitochondria 
were spread and dried on slide after which a few drops of Janus 
green B stain was added and kept for 5 min for staining. It was then 
rinsed once with distilled water and mounted in a drop of distilled 
water with a cover slip and imaged with a laser scanning confocal 
system (Zeiss LSM 510 META, Germany) and the stacked images 
were captured. The digitized images were then analyzed using 
image analysis system (ImageJ, NIH Software, Bethesda, MI) and the 
intactness of mitochondria of each image was measured and 
expressed as the % fluorescence intensity [21].  
Measurement of reactive nitrogen species (RNS) in 
mitochondria 
Nitric oxide concentrations in the incubated goat cardiac 
mitochondria were measured spectrophotometrically at 548 nm 
according to the method of Fiddler[22] by using Griess reagent [23]. 
The reaction mixture in a spectrophotometer cuvette (1 cm path 
length) contained 100 μL of Griess Reagent, 700 μL of the sample 
(i.e., incubated mitochondrial suspension) and 700 μL of distilled 
water. The nitric oxide concentration was expressed as µm 
Biochemical analysis 
Measurement of mitochondrial lipid peroxidation (LPO) level, 
reduced glutathione (GSH) and protein carbonyl (PCO) content 
The lipid peroxides in the incubated mitochondria were determined 
as thiobarbituric acid reactive substances (TBARS) according to the 
method of Buege et al. [24] with some modifications as adopted by 
Bandyopadhyay et al. [16]. The incubated mitochondria were mixed 
with thiobarbituric acid–trichloro acetic acid (TBA–TCA) reagent 
with thorough shaking and heated for 20 min at 800C. The samples 
were then cooled to room temperature. The absorbance of the pink 
chromogen present in the clear supernatant after centrifugation at 
8000rpm for 10 min at room temperature was measured at 532 nm 
using a UV–VIS spectrophotometer (Bio-Rad, Hercules, CA, USA). 
The values were expressed as nmols of TBARS/mg protein. 
The GSH content (as acid soluble sulfhydryl) was estimated by its 
reaction with DTNB (Ellman’s reagent) following the method of 
Sedlak et al. [25] with some modifications by Bandyopadhyay et al. 
[16]. Incubated mitochondria were mixed with Tris–HCl buffer, pH 
9.0, followed by DTNB for colour development. The absorbance was 
measured at 412 nm using a UV–VIS spectrophotometer to 
determine the GSH content. The values were expressed as nmole 
GSH/ mg protein. 
Protein carbonyl content was estimated by DNPH assay[26].0.25 ml 
of incubated mitochondrial suspension was taken in each tube and 
0.5 ml DNPH in 2.0 M HCl was added to the tubes. The tubes were 
vortexed every 10 min in the dark for 1 h. Proteins were then 
precipitated with 30% TCA and centrifuged at 2000rpm for 10 min. 
The pellet was washed carefully three times with 1.0 ml of ethanol: 
ethyl acetate (1:1, v/v). The final pellet was dissolved in 1.0 ml of 6.0 
M guanidine HCl in 20 mM potassium dihydrogen phosphate (pH 
2.3). The absorbance was determined spectrophotometrically at 370 
nm. The protein carbonyl content was calculated using a molar 
absorption coefficient of 2.2X 10-4 M-1 cm-1. The values were 
expressed as nmoles /mg of protein. 
Measurement of the activities of Mn-superoxide dismutase (Mn-
SOD), glutathione reductase (GR) and glutathione peroxidase 
(GPx) of goat cardiac mitochondria 
Manganese superoxide dismutase (Mn-SOD) activity was measured 
by pyrogallol autooxidation method [27].To 50 µl of the 
mitochondrial sample; 430 µl of 50 mM Tris–HCl buffer (pH 8.2) and 
20 µl of 2 mM pyragallol were added. An increase in absorbance was 
recorded at 420 nm for 3 min in a UV/VIS spectrophotometer. One 
unit of enzyme activity is 50% inhibition of the rate of autooxidation 
of pyragallol as determined by change in absorbance/min at 420 nm. 
The enzyme activity was expressed as units/ mg of protein  
The glutathione reductase (GR) assay was carried out according to 
the method of Krohne- Ehrich et al. [28]. The assay mixture in the 
final volume of 3 ml contained 50 mM phosphate buffer, 200 mM 
KCl, 1 mM EDTA and water. The blank was set with this mixture. 
Then, 0.1 mM NADPH was added together with suitable amount of 
incubated mitochondria (as the source of enzyme) into the cuvette. 
The reaction was initiated with 1 mM oxidized glutathione (GSSG). 
The decrease in NADPH absorption was monitored 
spectrophotometrically at 340 nm. The specific activity of the 
enzyme was calculated as units/min/mg of protein. 
The glutathione peroxidase (GPx) activity was measured according 
to the method of Paglia et al. [29] with some modifications as 
adopted by Dutta et al. [30]. The assay system contained, in a final 
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volume of 1 ml, 0.05 M phosphate buffer with 2 mM EDTA, pH 7.0, 
0.025 mM sodium azide, 0.15 mM glutathione, and 0.25 mM NADPH. 
The reaction was started by the addition of 0.36 mM H2O2. The linear 
decrease of absorbance at 340 nm was recorded using a UV/VIS 
spectrophotometer. The specific activity was expressed as Units/mg 
of protein. 
Measurement of the activities of pyruvate dehydrogenase and 
some of the Kreb’s cycle enzymes 
Pyruvate dehydrogenase (PDH) activity was measured spectro 
photometrically according to the method of Chretien et al. [31] with 
some modifications by following the reduction of NAD+ to NADH at 
340 nm using 50 mM phosphate buffer, pH 7.4, 0.5 mM sodium 
pyruvate as the substrate and 0.5 mM NAD+ in addition to the 
enzyme. The enzyme activity was expressed as units/mg of protein. 
Isocitrate dehydrogenase (ICDH) activity was measured according to 
the method of Duncan et al. [32] by measuring the reduction of NAD+ 
to NADH at 340 nm with the help of a UV–VIS spectrophotometer. 
One ml assay volume contained 50 mM phosphate buffer, pH 7.4, 0.5 
mM isocitrate, 0.1 mM MnSO4, 0.1 mM NAD+ and the suitable amount 
of incubated mitochondria as the source of enzyme. The enzyme 
activity was expressed as units/mg of protein. 
Alpha-ketoglutarate dehydrogenase (α-KGDH) activity was 
measured spectrophotometrically according to the method of 
Duncan et al. [32] by measuring the reduction of 0.35 mM NAD+ to 
NADH at 340 nm using 50 mM phosphate buffer, pH 7.4 as the assay 
buffer, incubated mitochondria as the source of enzyme and 0.1 mM 
α-ketoglutarate as the substrate. The enzyme activity was expressed 
as units/mg of protein.  
Succinate dehydrogenase (SDH) activity was measured spectro 
photometrically by following the reduction of potassium 
ferricyanide [K3Fe (CN) 6] spectrophotometrically at 420 nm 
according to the method of Veeger et al. [33] with some 
modifications. One ml assay mixture contained 50 mM phosphate buffer, 
pH 7.4, 2% (w/v) BSA, 4 mM succinate, 2.5 mM K3Fe(CN)6 and a 
suitable aliquot of the incubated mitochondria as the source of enzyme. 
The enzyme activity was expressed as units/mg of protein. 
Measurement of di-tyrosine fluorescence intensity 
Emission spectra of di-tyrosine, a product of tyrosine oxidation, 
were recorded in the range 380 to 440 nm (5 nm slit width) at 
excitation wavelength 325 nm (5 nm slit width) [34]. Emission 
spectra (from 425 to 480 nm, 5 nm slit width) of lysine conjugated 
with LPO products were recovered at excitation of 365 nm (5 nm slit 
width). Excitation spectra (from 325 to 380 nm, 5 nm slit width) 
were measured at 440 nm (5 nm slit width)[35]. 
Measurement of mitochondrial swelling 
Mitochondrial swelling was assessed by measuring the changes in 
absorbance of the suspension at 520 nm (Δ) by spectrophotometry 
according to Halestrap et al. [36]. The standard incubation medium 
for the swelling assay contained 250 mmol/L sucrose, 0.3 mmol/L 
CaCl2 and 10 mmol/L Tris (pH 7.4). Mitochondria (0.5 mg protein) 
were suspended in 3.6 mL of phosphate buffer. 1.8 mL of this 
suspension was added to both sample and reference cuvette and 6 
mmol/L succinate was added to the sample cuvette only, and at 520 
nm wavelength, changes in absorption  was recorded continuously 
at 25⁰C for 10 min. Swelling of mitochondria was evaluated 
according to decrease in values of in absorption at 520 nm. 
Scanning electron microscopy 
The mitochondrial suspension (250 µl) was centrifuged, and the 
supernatant was removed. The pellet was fixed overnight with 2.5% 
glutaraldehyde. After washing three times with PBS, the pellet was 
dehydrated for 10 min at each concentration of a graded ethanol 
series (50, 70, 80, 90, 95 and 100%).  
The pellet was immersed in pure tert-butyl alcohol and was then 
placed into a 4˚C refrigerator until the tert-butyl alcohol solidified. 
The frozen samples were dried by placing them into a vacuum 
bottle. Mitochondrial morphology was evaluated by scanning 
electron microscopy (SEM; Zeiss Evo 18 model EDS 8100). 
Estimation of protein 
The protein content of the isolated mitochondria was determined by 
the method of Lowry et al. [37]. 
 
Table 1: Specifications of silymarin 
Test 
No. 
Tests Results Specifications 
1. Description Brownish yellow 
fine powder 
Brownish yellow fine powder 
2. Solubility Complies Slightly soluble in ethyl acetate, soluble in hot methanol, insoluble in 
chloroform and water 
3. Identification: 




Retention time values of silybin and isosilybin peaks on the sample 
chromatogram obtained during content determination shall be equal to 
those of said peaks in the standard solution 
4. pH (1% suspension) 5.15 Between 4.5 to 6.0 
5. Loss on drying 0.54% Not more than 5.0% 
6. Sulphated Ash 0.22% Not more than 1.0% 
7. Heavy Metals Complies Not more than 100 ppm 
8. Microbial Test 
a) Bacteria 
b) Fungi 
c) Pathogenic Organisns: 
i) Escheria coli 
ii) Salmonella sp. 
iii) Pseudomonas aeruginisa 
iv) Staphylococcus aureous 
 
70 cfu/gm 






Not more than 1000 cfu/gm 
Not more than 100 cfu/gm 
Should be absent/10 g 
Should be absent/10 g 
Should be absent/10 g 
Should be absent/10 g 
9. Assay: 
i) Content of Silymarine (on 
as such basis) 
ii) Content of Silybin and 





Not less than 70% 
Not less than 70% 
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Statistical evaluation 
Each experiment was repeated at least three times. Data are 
presented as means ± S.E. Significance of mean values of different 
parameters between the treatments groups were analyzed using one 
way post hoc tests (Tukey’s HSD test) of analysis of variances 
(ANOVA) after ascertaining the homogeneity of variances between 
the treatments. Pairwise comparisons were done by calculating the 
least significance. Statistical tests were performed using Microcal 
Origin version 7.0 for Windows. 
RESULTS 
HPLC of the silymarin shows the retention times of the peaks of 
silybinin A and silybinin B in the chromatogram of the test solution 
corresponds to those in the chromatogram of the standard solution. 
HPLC analysis reported the content of silymarin as 70.32% and that 
of silybin and isosylibin as 30.14. Specification of silymarin has been 
described in table 1.The chemical structures of silybin and isosylibin 
have been shown in figure 1. 
 
Fig. 1: Chemical structures of silybin and isosilybin. 
 
The hydroxyl radical (•OH) scavenging ability of silymarin was 
studied in an in vitro chemically defined system using Cu2+ and 
ascorbic acid where •OH was generated which resulted in 
breakdown of deoxyribose to form a pink chromogen. Silymarin 
fraction directly scavenged •OH in a concentration-dependent 
manner exhibiting about 71.58% scavenging activity at a 
concentration of 0.50mg/ml (P<0.001 Vs. CuAs) and the minimum 
effective dose at which statistically significant change was observed 
was found to be 0.05mg/ml (Table 2). 
The effect of silymarin on the superoxide anion free radical 
scavenging ability was studied by following the rate of superoxide 
anion free radical mediated epinephrine oxidation. Increasing 
concentrations of silymarin altered the rate of superoxide anion free 
radical mediated epinephrine oxidation indicating a scavenging 
ability silymarin for O·2-.  
About 71.76% scavenging activity was observed at a concentration 
of 0.50mg/ml of Silymarin which was statistically highly significant. 
The values in the figure are Mean ± SE of at least four sets of 
experiments; P<0.001 vs. % of control epinephrine auto-oxidation 
(Table 2). 
The H2O2 scavenging activity of Silymarin, if any, was also tested in 
vitro by studying the breakdown of H2O2 at 240 nm. Silymarin 
scavenged hydrogen peroxide in a dose dependent manner. The 
maximum scavenging activity was observed at concentration of 
0.50mg/ml (P<0.001Vs. control hydrogen peroxide breakdown) 
(Table 2). 
DPPH appears as a free radical in methanolic solution. In this 
medium, Silymarin scavenged this free radical in a dose-dependent 
manner. Maximum scavenging ability (32.32%) (P< 0.001) was 
exhibited at a concentration of 0.50mg/ml of silymarin(Table 2).
 
Table 2: Antioxidant activity of silymarin 
Groups  Hydroxyl radical scavenging 
activity (n moles/ml of 
reaction mixture)  
Superoxide anion free radical 
scavenging activity (Change in 
OD at 480 nm/min)  
Hydrogen peroxide 
scavenging activity (Units/ 
min/mg of protein)  
DPPH radical scavenging 
activity (Units/ min/mg of 
protein)  
Control  0.25 ± 0.008  0.085 ± 0.001  0.75 ± 0.030 0.99 ± 0.003  
CuAs  0.95 ± 0.002#  ---------  ---------   ---------  
S0.05  0.64 ± 0.007  0.066 ± 0.000  0.64 ± 0.080 0.96 ± 0.000  
S0.10  0.53 ± 0.001  0.052 ± 0.003  0.59 ± 0.001  0.84 ± 0.000  
S0.25 0.42 ± 0.002  0.046 ± 0.002   0.41 ± 0.030  0.77 ± 0.002  
S0.50 0.27 ± 0.004 *  0.024 ± 0.006* 0.32 ± 0.002* 0.67 ± 0.000* 
CuAs = copper-ascorbate incubated group; S0.05-0.50= group incubated with silymarin at the dose of 0.05-0.50mg/ml respectively; The values are 
expressed as Mean ± S.E.; #P < 0.001 as compared to control values using ANOVA; * P < 0.001 as compared to CuAs-treated values using ANOVA. 
 
Figure 2(A-C) depicts a significant decrease in the mitochondrial 
intactness following the incubation of mitochondria with copper-
ascorbate (75.45%, P < 0.001 vs. control). This decreased level of 
mitochondrial intactness were found to be significantly protected 
from being altered (3.12 fold compared to copper-ascorbate-
incubated group, P < 0.001) when the mitochondria were co-
incubated with copper-ascorbate and silymarin(0.50mg/ml), 
indicating the ability of silymarinto protect the mitochondria against 
copper-ascorbate induced changes in mitochondrial swelling which 
may be due to oxidative stress. Figure 2(D-E) (magnification 40X) 
reveals the mitochondria of various groups. It depicts a decrease in 
the mitochondrial intactnes following the incubation of 
mitochondria with copper-ascorbate.  
This decreased level of mitochondrial intactness was found to be 
protected from being altered when the mitochondria were co-
incubated with copper-ascorbate and silymarin in a dose-dependent 
manner. 
The level of NO in mitochondria in copper-ascorbate incubated 
group was found to be increased significantly (figure. 3) when 
compared to control group by 1.33 fold (#P≤ 0.001). However, a 
dose-dependent protection of the level of NO was observed when 
the cardiac mitochondria were co-incubated with copper-ascorbate 
and increasing concentrations of silymarin. At 0.50mg/ml, 
silymarinwas found to maximally protect the level of mitochondrial 
NO from being altered (57.57% protection, *P≤ 0.001). 
A significant increase in cardiac mitochondrial LPO level following 
the incubation of mitochondria with copper-ascorbate (1.27 fold, #P 
< 0.001 vs. control) was observed. This elevated level of lipid 
peroxidation products were found to be protected from being 
increased significantly (60.00% from copper-ascorbate-treated 
group, *P < 0.001Vs. Cu-ascorbate) when the mitochondria were co-
incubated with copper-ascorbate and silymarin(0.50mg/ml), indicating 
the ability of silymarin to protect the mitochondria against oxidative 
stress-induced changes due to copper-ascorbate (Table 3). 
Copper-ascorbate caused significant decrease in cardiac 
mitochondrial reduced GSH content (45.77%, #P< 0.001 vs. control). 
This decreased level of reduced GSH content was found to be 
protected significantly in a dose-dependent manner. An increase of 
75.42% was observed compared to copper-ascorbate-treated group, 
(*P < 0.001 Vs. Cu-As) when the mitochondria were co-incubated 
with copper-ascorbate and silymarin(0.50mg/ml) (Table 3). 
Measurement of protein carbonyl content showed a significant 
increase in cardiac mitochondrial protein carbonyl following the 
incubation of mitochondria with copper-ascorbate (1.74 fold, #P < 
0.001 vs. control). 
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Fig. 2: Changes of intactness of mitochondria. (A-B) Janus green 
B stained (40X magnification), (C) graphical representation of 
changes of mitochondrial intactness and (D-E) Janus green B 
stained (Bright field microscopy; 40X magnification); CuAs = 
copper-ascorbate incubated group; S0.05-0.50= group 
incubated with Silymarin at the dose of 0.05-0.50mg/ml 
respectively (positive control); CuAs- S0.05-0.50= group co-
incubated with copper-ascorbate and silymarin at the dose of 
0.05-0.50mg/ml respectively; The values are expressed as 
Mean ± S.E.; #P < 0.001 compared to control values using 
ANOVA. *P < 0.001 compared to copper-ascorbate incubated 
values using ANOVA. 
 
Fig. 3: Protective effect of silymarin against copper-ascorbate-
induced increase in nitric oxide concentration. CuAs = copper-
ascorbate incubated group; S0.05-0.50= group incubated with 
silymarin at the dose of 0.05-0.50mg/ml respectively (positive 
control); CuAs- S0.05-0.50= group co-incubated with copper-
ascorbate and silymarin at the dose of 0.05-0.50mg/ml 
respectively; The values are expressed as Mean ± S.E.; #P < 
0.001 compared to control values using ANOVA. *P < 0.001 
compared to copper-ascorbate incubated values using ANOVA. 
 
This elevated level of protein carbonyl content was found to be 
protected significantly (66.40% from copper-ascorbate-incubated 
group, *P <0.001) when the mitochondria were co-incubated with 
copper-ascorbate and silymarin (0.50mg/ml) (Table 3). 
 
Table 3: Protective effect of silymarin against copper-ascorbate induced alteration in the biomarkers of oxidative stress in goat heart 
mitochondria 
Groups LPO level (nmol TBARS/ mg of protein) GSH (nmole GSH/ mg of protein) Protein carbonyl (nmoles/ mg of protein) 
Control 0.75± 0.009 32.86 ± 3.0 7.50 ± 0.0 
CuAs 1.7± 0.001# 17.82 ± 1.8# 17.53 ± 0.2 # 
S0.05 0.74±0.003 33.81 ± 2.0 7.55 ± 0.2 
S0.10 0.75±0.005 33.84 ± 0.1 7.56 ± 0.0 
S0.25 0.74±0.003 32.98 ± 0.6 7.52 ± 0.2 
S0.50 0.74±0.001 33.07 ± 1.7 7.50 ± 0.7 
CuAs-S0.05 1.44 ± 0.002 19.97 ± 0.5 17.63 ± 0.8 
CuAs-S0.10 1.20 ± 0.001 23.13 ± 5.1 11.59± 0.0 
CuAs-S0.25 0.74 ± 0.002 25.50 ± 2.9 7.17 ± 0.1 
CuAs-S0.50 0.68 ± 0.002* 31.26 ±1.2* 5.89 ± 0.2* 
CuAs = copper-ascorbate incubated group; S0.05-0.50= group incubated with silymarin at the dose of 0.05-0.50mg/ml respectively (positive 
control); CuAs-S0.05-0.50= group co-incubated with copper-ascorbate and silymarin at the dose of 0.05-0.50mg/ml respectively; The values are 
expressed as Mean ± S.E.; #P < 0.001 as compared to control values using ANOVA; * P < 0.001 as compared to CuAs-treated values using ANOVA. 
 
A highly significant elevation (1.27 fold,#P < 0.001 vs. control group) 
was observed in the activity of Mn-SOD following incubation of 
mitochondria with copper-ascorbate. The activity of this enzyme 
was found to be protected from being increased when the 
mitochondria were co-incubated with copper-ascorbate and 
silymarin. Silymarin protected Mn-SOD activity by 56.65% (*P < 
0.001 vs. copper-ascorbate-treated group) at the dose of 0.50mg/ml 
(Table 4). Silymarin by itself has no effect on the activity of Mn-SOD. 
A highly significant decrease (64.81%, #P < 0.001 vs. control group) 
in the activity of GPx following the incubation of mitochondria with 
copper-ascorbate was observed. The GPx activity was protected 
from being decreased when the mitochondria were co-incubated 
with copper-ascorbate and silymarin. Silymarinnot only protected 
but also stimulated GPx activity 2.54 fold (*P <0.001 vs. copper-
ascorbate-treated group) at the dose of 0.50mg/ml (Table 4). 
However, Silymarin by itself has no effect on the activity of GPx. 
There is also a highly significant decrease (58.03%, #P < 0.001 vs. 
control group) in the activity of GR following incubation of 
mitochondria with copper-ascorbate. The GR activity was found to 
be protected from being decreased when the mitochondria were co-
incubated with copper-ascorbate and silymarin. Silymarin protected 
GR activity by about 1.78 fold (*P < 0.001 vs. copper-ascorbate-
treated group) at the dose of 0.50 mg/ml (Table 4). Silymarin by 
itself, however, has no effect on the activity of GR. 
The incubation of the goat heart mitochondria with copper-
ascorbate inhibits pyruvate dehydrogenase activity (54.11%, 
#P<0.001 vs. control). When the mitochondria were co-incubated 
with copper-ascorbate and silymarin, the activity of the enzyme, 
however, was found to be significantly protected from being 
decreased compared to the activity observed in the copper-
ascorbate-incubated group (1.29 fold increased,*P<0.001 vs. copper-
ascorbate-incubated group) at the dose of 0.50mg/ml (Figure 4). 
Measurement of isocitrate dehydrogenase (ICDH) activity reveals 
that the incubation of the mitochondria with copper-ascorbate 
significantly inhibits isocitrate dehydrogenase activity (55.78%, 
#P<0.001 vs. control). The activity of the enzyme was found to be 
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completely protected when mitochondria were co-incubated with 
silymarin at the dose of 0.50mg/ml (1.54 fold increased, *P<0.001 
vs. Cu-As) (Figure 4).  Alpha keto glutarate dehydrogenase (α-KGDH) 
activity was found to be decreased when mitochondria were 
incubated with copper-ascorbate (54.25%, P<0.001 vs. control). The 
activity of the enzyme was found to be significantly protected from 
being decreased when the mitochondria were co-incubated with 
0.50mg/ml dose of silymarin (1.27 fold higher, *P<0.001 vs. copper-
ascorbate-incubated group) (Figure 4).  
 
 
Fig. 4: Protective effect of silymarin against copper-ascorbate-
induced alteration in the pyruvate dehydrogenase and other 
Kreb’s cycle enzymes in goat heart mitochondria. CuAs = 
copper-ascorbate incubated group; S0.05-0.50= group 
incubated with silymarin at the dose of 0.05-0.50mg/ml 
respectively (positive control); CuAs- S0.05-0.50= group co-
incubated with copper-ascorbate and silymarin at the dose of 
0.05-0.50mg/ml respectively; The values are expressed as 
Mean ± S.E.; #P < 0.001 compared to control values using 
ANOVA. *P < 0.001 compared to copper-ascorbate incubated 
values using ANOVA. 
The succinate dehydrogenase (SDH) activity was found to be 
significantly decreased when mitochondria were incubated with 
copper-ascorbate (70.17%, #P<0.001 vs. control). The enzyme 
activity was found to be significantly protected from being 
decreased when the mitochondria were co-incubated with 
0.50mg/ml dose of the silymarin (2.80 fold higher, *P<0.001 vs. 
copper-ascorbate-incubated group) (Figure 4). 
The mitochondria were added to the reaction buffer (at pH 7.2) or 
0.3 mmol/L of CaC12. After that the mitochondrial absorbance at 520 
nm declined, indicating mitochondrial swelling due to alteration in 
osmotic pressure. The extent of decrease in absorbance in the 
mitochondria incubated with copper-ascorbate was found to be 
lower compared to the control group (Figure 5A), demonstrating 
that incubation with copper-ascorbate caused oxidative damage of 
mitochondria.  
The absorbance was found to be significantly increased when the 
goat heart mitochondria were co-incubated with copper-ascorbate 
and silymarin (at a dose of 0.50mg/ml) compared to mitochondria 
incubated with copper-ascorbate only. This indicates that silymarin 
has the potential to improve impaired mitochondrial function. 
That copper-ascorbate induced oxidative stress has a direct effect on 
the oxidation level of amino acid is evident from increased di-
tyrosine formation (2.00 fold increase, #P<0.001 compared to 
control group) (Figure 5B) as observed using fluorimetric analysis of 
this amino acids’ basal auto-fluorescence.  
Co-incubation of cardiac mitochondria with copper-ascorbate and 
silymarin (at the dose of 0.50mg/ml) was found to protect these 
molecules from losing their original configuration as indicated by 
recovered auto-fluorescence level for di-tyrosine formation (45.83% 
protection, *P<0.001 compared copper-ascorbate-incubated group). 
The silymarin by itself has no effect on the di-tyrosine fluorescence 
of cardiac mitochondria. 
 
Table 4: Protective effect of silymarin against copper-ascorbate induced alteration in the activities of antioxidant enzymes of goat heart 
mitochondria 
Groups Mn-superoxide dismutase activity 
(Units/mg of protein) 
Glutathione peroxidase activity (Units/ 
mg of protein) 
Glutathione reductase activity (Units/ 
mg of protein) 
Control 67.91±1.27 29.67±1.29 43.89 ± 0.11 
CuAs 154.39±8.21# 10.44±0.09# 18.42 ± 0.51# 
S0.05 67.24±2.40 29.45±0.82 43.87 ± 1.70 
S0.10 67.50±4.50 28.93±0.84 43.15 ± 0.05 
S0.25 67.93±0.003 29.55±0.05 43.88 ± 0.01 
S0.50 67.29±0.19 29.53±2.17 43.04 ± 0.08 
CuAs-S0.05 141.40±3.89 13.84±0.03 25.33 ± 0.12 
CuAs-S0.10 125.51±7.34 20.39±0.17 32.94 ± 0.09 
CuAs-S0.25 84.10±0.04 29.49±1.02 43.61± 0.01 
CuAs-S0.50 65.39±0.21* 36.97±0.19* 51.27 ± 0.02* 
CuAs = copper-ascorbate incubated group; S0.05-0.50= group incubated with silymarin at the dose of 0.05-0.50mg/ml respectively (positive 
control); CuAs-S0.05-0.50 = group co-incubated with copper-ascorbate and silymarin at the dose of 0.05-0.50mg/ml respectively; The values are 
expressed as Mean ± S.E.; #P < 0.001 as compared to control values using ANOVA; * P < 0.001 as compared to CuAs-treated values using ANOVA. 
 
Figure 5(C-F) shows the changes brought about to the cardiac 
mitochondrial surface following incubation with copper-ascorbate 
studied through scanning electron microscopy. The figure shows a 
perforated surface with convoluted membranes. Moreover, the 
mitochondria were found to be markedly contracted, with large 
membrane blebs covering its surface. However, when the cardiac 
mitochondria were co-incubated with copper-ascorbate and 
silymarin (at 0.50mg/ml), the changes on the mitochondrial surface 
were found to be significantly protected from being taken place. 
DISCUSSION 
Reactive oxygen species (ROS) are generated due to redox 
imbalance in tissues, which is responsible for tissue damage by 
modification of lipid, proteins and nucleic acids. In our in vitro 
experimental system Cu-ascorbate was used as an inducer of 
oxidative stress in goat heart mitochondria. The mechanism of 
generation of OH in this system is as follows: 
 
As evident from the above reaction, O2- anion radical is generated by 
Cu2+. The activity of superoxide dismutase which is found to be 
increased in mitochondrial compartments may be due to generation 
of this O2-anion radical. As the catalase enzyme is absent in 
mitochondria, so it is quite impossible to quench this H2 O2 overload. 
Hence, this hydrogen peroxide generates.OH responsible for lipid 
peroxidation, protein carbonylation, depletion of mitochondrial GSH 
(that is also evident from decreased activities of GPx and GR). 
Additionally the generated hydroxyl radical causes declining 
activities of NAD linked enzymes like pyruvate dehydrogenase, α-
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keto glutarate dehydrogenase, isocitrate dehydrogenase as well as 
FAD linked enzyme i.e. succinate dehydrogenase (all of them are 
associated with electron transport chain for oxidative 
phosphorylation.) that again will generate more superoxide anion 
through electron transport chain and which will follow above 
reaction scheme and overload of excess hydroxyl radical will be 
exerted on the mitochondria and finally mitochondria will be fragile 
as evident from our studies using scanning electron microscopy. 
 
 
Fig. 5: Protective effect of silymarin against copper-ascorbate-
induced (A) decrease in mitochondrial swelling and (B) 
increase in di-tyrosine level. (C-F) Scanning electron 
micrograph (X6000) of mitochondrial surface. Arrow heads 
indicate perforated surface of mitochondria. CuAs = copper-
ascorbate incubated group; S0.50= group incubated with 
silymarin at the dose of 0.50mg/ml respectively (positive 
control); CuAs-S0.50= group co-incubated with copper-
ascorbate and silymarin at the dose of 0.50mg/ml respectively; 
The values are expressed as Mean ± S.E.; #P < 0.001 compared to 
control values using ANOVA. *P < 0.001 compared to copper-
ascorbate incubated values using ANOVA. 
 
Oxidative damage in a cell or tissue occurs when the concentration 
of reactive oxygen species generated exceeds the antioxidant 
capability of the cell [38]. The status of lipid peroxidation as well as 
altered levels of certain endogenous radical scavengers is taken as 
direct evidence for oxidative stress [39]. Free radical scavenging 
enzymes like superoxide dismutase (SOD), glutathione peroxidase 
(GPx) and glutathione reductase (GR) protect the biological systems 
from oxidative stress. The SOD dismutates superoxide anion free 
radicals (O2.−) into hydrogen peroxide (H2O2) and O2 [40]. 
Glutathione peroxidase also functions in detoxifying H2O2 similar to 
catalase. Thus, SOD and glutathione peroxidase act mutually and 
constitute the enzymatic antioxidative defense mechanism against 
reactive oxygen species [41].  
The alteration in the activities of these enzymes in the present study 
could be attributed to the excessive utilization of these enzymes in 
inactivating the free radicals generated during the incubation of 
mitochondria with copper-ascorbate. This is further substantiated 
by an elevation in the levels of lipid peroxidation. Restoration in the 
levels of lipid peroxidation after administration of silymarin could 
be related to its ability to scavenge reactive oxygen species, thus 
preventing further damage to membrane phospholipids. Our results 
are in line with previous studies by Ramakrishnan et al. [42] who 
have shown that silymarin exhibits excellent antioxidant property. 
 Therefore, this property of silymarin might have resulted in the 
recoupment in the activities of the above antioxidant enzymes to 
normalcy. The above mentioned results of our experiments inspired 
us to consider it as a potent antioxidant, which is strongly evident 
from its ROS scavenging activities i.e. direct scavenging ability of 
superoxide anion free radical, free hydroxyl radical and hydrogen 
peroxide. On another side, it also prevents Cu-ascorbate induced 
alteration in mitochondria in a dose dependent manner. It also 
stimulates cellular antioxidant i.e. GSH synthesis, evident from result 
of glutathione reductase assay and reduced glutathione.  
Mainly, it also prevented lipid peroxidation and protein 
carbonylation in Cu-ascorbate induced samples of mitochondria 
through removal of hydroxyl radicals. It also ameliorated oxidative 
stress by protecting the activities of Kreb’s cycle enzymes. Reduce 
levels of activities of these enzymes may cause generation of 
superoxide anion radical using molecular oxygen as an electron sink. 
Superoxide anion free radicals if generated will cause hydroxyl 
radical generation, which in turn will result in oxidative cell damage. 
By altering liver cell membranes, silymarin inhibits toxin uptake and 
stimulates cell regeneration [8]. Silymarin’s potent antioxidant 
activity helps to quell inflammation and replenish glutathione [8]. 
Glutathione is the chief antioxidant inside most living cells and is the 
main line of defense against free radical damage. It is found in high 
concentrations in the liver. In a review of viral hepatitis studies, 
silymarin decreased liver enzymes known as serum transaminases 
[43] and improved symptoms and general well-being [44]. 
Regarding activity against hepatitis C virus, silymarin and its 
components were anti-inflammatory. All compounds blocked virus-
induced oxidative stress. Multiple assays suggest that numerous milk 
thistle compounds may help ameliorate hepatitis C disease [45]. In 
conclusion, silymarin can be very effective antioxidant and can 
protect biological systems against the oxidative stress that is found 
to be an important pathophysiological event in a variety of diseases 
including aging, cancer, diabetes, cardiovascular disorders and 
rheumatoid arthritis. As far as we know, this is the first report to 
describe an antioxidant mechanism(s) (Figure 6) of protective effect of 
silymarin toward copper-ascorbate-induced mitochondrial oxidative 
damage. Therefore, as it is stated above silymarin shows high 
antioxidant capacity mainly due to its phenolic compounds and inhibits 
lipid peroxidation in mitochondrial in vitro models, the present study 
suggests that silymarin may be used in preventing free radical-related 
diseases as a dietary natural antioxidant supplement. 
 
 
Fig. 6: Schematic diagram representing the antioxidant 
mechanism(s) of protection of Silymarinagainst copper-
ascorbate induced oxidative damages in cardiac mitochondria. 
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